ASH 2022 | Addressing the potential role of immunotherapy in the frontline treatment of ALL
Bela Wrench
• 12 Dec 2022
Bela Wrench, MBBS, MD (res), MRCP, FRCPath, Barts Cancer Institute, London, UK, shares some highlights in acute lymphoblastic leukemia (ALL) from the 2022 ASH Annual Meeting, emphasizing the growing role of immunotherapy in the frontline treatment of adult patients with ALL, and trials evaluating this. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer: Membership on an entity’s Board of Directors or advisory committees.
